Canadian Cancer Trials Group Bulletins

Office of Compliance and Oversight

Use of Positron Emitting Radiopharmaceuticals

As sponsor, Canadian Cancer Trials Group has a NEW process to ensure that Canadian Member Centres are using Positron Emitting Radiopharmaceuticals (PER) manufactured in Canada, as per Health Canada requirements.

A Positron Emitting Radiopharmaceutical Attestation (PERA) form will be sent annually to Canadian Member Centre Representatives (CENREP) and Contact Clinical Research Associates (CCRA) to attest that PERs used at their site are manufactured in Canada. The form should be completed, signed by the CENREP, and returned to Canadian Cancer Trials Group. Centre-specific information from the completed form will include: use of PET at the centre; source of PER, either on-site or from elsewhere in Canada, and the PER name. If any of this information changes, centres will be required to submit a revised PERA to Canadian Cancer Trials Group within 30 days of the change.

This form will be sent to Canadian members in the near future. If you have any questions, please contact the Ethics and Regulatory Team Leader at